Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glyoxyldiureide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Eshelman Ventures
Deal Size : $12.5 million
Deal Type : Financing
Paradigm Therapeutics gets Eshelman Funding for SD-101 Topical EB Treatment
Details : The financing aims to advance the late-stage program Zorblisa (allantoin), which is being evaluated for the treatment of Epidermolysis Bullosa.
Product Name : Zorblisa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : Glyoxyldiureide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Eshelman Ventures
Deal Size : $12.5 million
Deal Type : Financing